Close
Novotech

Autopack to host biggest packaging machinery stand at PPMA Total 2025

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

Leading independent integrator of packaging lines Autopack will showcase a range of cutting-edge automated equipment at PPMA Total 2025, which takes place at Birmingham’s NEC from 23-25 September. The Hereford-based business will take its largest individual stand to date in what it believes is the largest packaging machinery stand at the show.

Autopack 1

With 15 machines on stand B20, Autopack will be giving pride of place to four primary machines in filling, capping, horizontal Form Fill Seal (HFFS) and Vertical Form Fill Seal (VFFS). The VFFS machine will demonstrate a new brick pack format for coffee beans as one of Autopack’s latest packaging innovations. The block bottom bag has a roll top finish secured using a resealable label and delivers a new packaging format for the hugely popular coffee bean sector.

“We believe that the coffee market has huge potential and that packers are after something new,” said Autopack Sales Director Jonathon Stewart. “The different style bag will deliver a fresh packaging format that can shake up the sector and we invite those in the sector to come and see this latest innovation.”

As well as VFFS and HFFS machines, Autopack provides sachet, stick and pouch equipment either pre-made or from film on the reel. These can be tailored with zippers, spouts and custom shapes, with visitors able to discuss their requirements with a 20-strong team, who will be on Autopack’s stand throughout the three-day show.

For those looking at rigid packaging solutions, Autopack supplies de-palletising, un-scrambling rinsing systems for bottles, jars, tins and containers. In addition, it can provide the associated conveyors onto a wide range of filling machines (single head up to 12 head) with capping solutions such as screw-on, pilfer proof and vacuum twist capping machines.

“PPMA Total 2025 is the perfect platform to highlight our innovations in the sector,” added Jonathon. “We can interact with key decision makers from big name retailers and brand owners, as well as start-ups looking for advice on what technology best suits their product.”

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »